Encouraging early data on Coya Therapeutics' COYA 301 in Alzheimer's

Some positive data from Coya Therapeutics (Nasdaq: COYA) lifted the US biotech’s shares 10% in normal trading and a further 6.4% to $6.20 in after-hours activity on Tuesday.

Coya, which is developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, reported results from an open-label proof-of-concept clinical study for COYA 301 in patients with Alzheimer’s disease (AD) at the Keystone Conference ‘Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development’ in Whistler, Canada.

The study enrolled eight patients with confirmed presence of brain amyloid pathology and baseline MMSE scores between 12 and 25. The patients were treated with five-day-courses of COYA 301 for four monthly cycles and were followed for two months post-treatment. Treg function and numbers, serum biomarkers of inflammation, and cognitive functioning as measured by the ADAS-Cog, CDR-SB and MMSE assessment tools were evaluated.